HC Wainwright Reaffirms Neutral Rating for Aardvark Therapeutics (NASDAQ:AARD)

Aardvark Therapeutics (NASDAQ:AARD)‘s stock had its “neutral” rating restated by research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports.

AARD has been the topic of several other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Aardvark Therapeutics in a research note on Monday, December 29th. William Blair started coverage on shares of Aardvark Therapeutics in a research report on Friday, December 12th. They set an “outperform” rating on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Aardvark Therapeutics in a report on Friday, November 14th. B. Riley Financial started coverage on shares of Aardvark Therapeutics in a report on Wednesday, January 28th. They set a “buy” rating and a $32.00 price objective on the stock. Finally, BTIG Research reduced their target price on Aardvark Therapeutics from $26.00 to $9.00 and set a “buy” rating for the company in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.36.

Aardvark Therapeutics Price Performance

Shares of NASDAQ:AARD opened at $12.49 on Monday. Aardvark Therapeutics has a 1 year low of $4.88 and a 1 year high of $17.94. The business’s 50-day moving average is $13.57 and its 200-day moving average is $12.18. The company has a market capitalization of $271.91 million and a price-to-earnings ratio of -5.89.

Insider Transactions at Aardvark Therapeutics

In related news, CEO Tien-Li Lee acquired 7,000 shares of the firm’s stock in a transaction on Thursday, December 11th. The stock was purchased at an average cost of $14.48 per share, with a total value of $101,360.00. Following the acquisition, the chief executive officer owned 1,551,613 shares of the company’s stock, valued at approximately $22,467,356.24. This trade represents a 0.45% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Nelson Sun bought 3,000 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The shares were bought at an average cost of $14.40 per share, for a total transaction of $43,200.00. Following the transaction, the chief financial officer owned 108,484 shares of the company’s stock, valued at $1,562,169.60. The trade was a 2.84% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

Hedge Funds Weigh In On Aardvark Therapeutics

Large investors have recently bought and sold shares of the stock. Citadel Advisors LLC boosted its holdings in Aardvark Therapeutics by 5.9% during the 3rd quarter. Citadel Advisors LLC now owns 1,359,883 shares of the company’s stock worth $18,073,000 after acquiring an additional 76,151 shares during the last quarter. Laurion Capital Management LP lifted its position in shares of Aardvark Therapeutics by 6.1% during the third quarter. Laurion Capital Management LP now owns 1,049,721 shares of the company’s stock valued at $13,951,000 after purchasing an additional 60,653 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Aardvark Therapeutics by 20.6% during the third quarter. Vanguard Group Inc. now owns 555,721 shares of the company’s stock valued at $7,386,000 after purchasing an additional 94,744 shares in the last quarter. Millennium Management LLC boosted its holdings in Aardvark Therapeutics by 51.2% during the fourth quarter. Millennium Management LLC now owns 483,340 shares of the company’s stock worth $6,344,000 after purchasing an additional 163,717 shares during the last quarter. Finally, SymBiosis Capital Partners LLC bought a new stake in Aardvark Therapeutics in the 4th quarter worth about $6,255,000.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.